Silo Pharma Advances PTSD Intranasal Therapy Safety Studies

Silo Pharma, Inc. is advancing its lead drug candidate SPC-15, an intranasal serotonin 5-HT4 receptor agonist designed to treat post-traumatic stress disorder (PTSD) and related stress-induced psychiatric disorders, toward human clinical trials. The company has partnered with Veloxity Labs to conduct GLP-compliant toxicology and toxicokinetics studies and with Frontage Laboratories to perform an FDA-requested 7-day safety and toxicology large animal study, both critical steps for the Investigational New Drug (IND) application expected in 2025. CEO Eric Weisblum emphasized the importance of these studies for supporting the IND submission and maintaining the timeline for a Phase 1 clinical trial. SPC-15 benefits from an exclusive global license from Columbia University and may qualify for the FDA’s expedited 505(b)(2) regulatory pathway, potentially accelerating its approval process. Financially, Silo Pharma maintains strong liquidity and impressive gross profit margins, supporting its research and development activities. The company’s broader portfolio includes treatments for fibromyalgia, chronic pain, and central nervous system diseases, developed in collaboration with leading universities and laboratories.